Cogent Biosciences, Inc. (COGT) shareholders
Close on Nov 17, 2026Market cap $4.83BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 16,569,256 | 15.00% | 13G (passive) amendment | Dec 31, 2024 |
| Fairmount Healthcare Fund II GP LLC Joint filing with Fairmount Funds Management LLC (8.60%) | 15,356,918 | 8.60% | 13D (active) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 13,593,063 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| Paradigm BioCapital Advisors GP LLC Joint filing with Paradigm BioCapital Advisors LP (9.10%), Senai Asefaw, M.D. (9.10%) and 1 more | 10,352,449 | 9.10% | 13G (passive) amendment | Jun 30, 2025 |
| Deerfield Mgmt, L.P. Joint filing with Deerfield Management Company, L.P. (6.49%), Deerfield Partners, L.P. (6.49%) and 1 more | 9,053,118 | 6.49% | 13G (passive) | Jul 7, 2025 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (7.90%), Senai Asefaw, M.D. (7.90%) and 1 more | 8,963,655 | 7.90% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 8,691,589 | 5.08% | 13G (passive) | Jun 30, 2026 |
| Kynam Capital Management, LP Joint filing with Kynam Capital Management GP, LLC (5.54%), Yue Tang (5.54%) | 7,886,172 | 5.54% | 13G (passive) amendment | Sep 30, 2025 |
| Bong Y Koh Joint filing with Venrock Healthcare Capital Partners II, L.P. (5.80%), VHCP Co-Investment Holdings II, LLC (5.80%) and 7 more | 6,446,917 | 5.80% | 13G (passive) amendment | Sep 30, 2024 |
| Michael Kramarz Joint filing with Commodore Capital LP (5.50%), Commodore Capital Master LP (5.50%) and 1 more | 6,408,060 | 5.50% | 13G (passive) | Jul 7, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COGT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 25,681,174 | 14.80% | $993.86M | +2,558,426 | 0.04% |
| BlackRock, Inc. | 17,352,646 | 10.00% | $671.55M | +1,307,632 | 0.01% |
| Vanguard Portfolio Management LLC | 8,072,411 | 4.65% | $312.40M | +739,078 | 0.01% |
| Vanguard Capital Management LLC | 7,412,330 | 4.27% | $286.86M | +517,371 | 0.01% |
| State Street Corp | 6,964,919 | 4.01% | $269.54M | +1,301,376 | 0.01% |
| Jupiter Topco LLC | 6,624,848 | 3.82% | $256.42M | New | 0.10% |
| Fairmount Funds Management LLC | 5,503,418 | 3.17% | $212.98M | – | 14.08% |
| Deerfield Management Company, L.P. (Series C) | 5,006,104 | 2.88% | $193.74M | −4,037,799 | 2.02% |
| TCG Crossover Management, LLC | 4,854,436 | 2.80% | $187.87M | −92,458 | 4.52% |
| Price T Rowe Associates Inc /Md/ | 4,652,727 | 2.68% | $180.06M | +1,439,912 | 0.02% |
| Geode Capital Management, LLC | 4,508,998 | 2.60% | $174.53M | +809,479 | 0.01% |
| Wellington Management Group Llp | 4,343,977 | 2.50% | $168.11M | +765,355 | 0.03% |
| Kynam Capital Management, LP | 3,667,097 | 2.11% | $141.92M | −370,234 | 7.84% |
| Lord, Abbett & Co. LLC | 3,431,030 | 1.98% | $132.78M | +249,760 | 0.38% |
| Polar Capital Holdings Plc | 3,232,905 | 1.86% | $125.11M | New | 0.30% |
| Commodore Capital LP | 3,050,000 | 1.76% | $118.04M | +161,993 | 7.03% |
| Assenagon Asset Management S.A. | 2,883,512 | 1.66% | $111.59M | +2,587,862 | 0.07% |
| Invesco Ltd. | 2,609,141 | 1.50% | $100.97M | +179,512 | 0.01% |
| Woodline Partners LP | 2,603,162 | 1.50% | $100.74M | +1,093,605 | 0.31% |
| Pictet Asset Management Holding SA | 2,393,515 | 1.38% | $92.63M | +594,747 | 0.09% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 323 | 195M | 100.0% | 66 / 137 | 86 / 44 | 40M | 26M |
| Q1 2026 | 305 | 187M | 100.0% | 80 / 116 | 82 / 36 | 45M | 21M |
| Q4 2025 | 267 | 174M | 100.0% | 95 / 93 | 64 / 21 | 44M | 28M |
| Q3 2025 | 195 | 159M | 91.8% | 41 / 87 | 46 / 24 | 50M | 26M |
| Q2 2025 | 180 | 136M | 78.2% | 30 / 78 | 37 / 35 | 20M | 18M |
| Q1 2025 | 186 | 134M | 76.9% | 32 / 67 | 50 / 20 | 21M | 9M |
| Q4 2024 | 176 | 122M | 70.1% | 38 / 63 | 46 / 23 | 19M | 19M |
| Q3 2024 | 161 | 122M | 70.2% | 32 / 53 | 48 / 19 | 17M | 10M |
| Q2 2024 | 149 | 122M | 70.5% | 28 / 55 | 48 / 22 | 28M | 19M |
| Q1 2024 | 146 | 113M | 65.1% | 33 / 63 | 37 / 30 | 32M | 12M |
| Q4 2023 | 144 | 94M | 54.1% | 36 / 61 | 30 / 24 | 23M | 20M |
| Q3 2023 | 135 | 91M | 52.4% | 12 / 58 | 36 / 13 | 11M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
351 funds held COGT in Q2 2026, 37% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of COGT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,156,952 | 2.97% | $199.57M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,279,868 | 2.47% | $165.63M | 0.20% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,724,033 | 2.15% | $144.12M | 0.08% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,172,989 | 1.83% | $122.79M | 1.14% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 2,509,157 | 1.45% | $97.68M | 1.11% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 2,358,212 | 1.36% | $91.26M | 0.13% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,959,435 | 1.13% | $75.83M | 0.08% | Jun 30, 2026 |
| Fidelity OTC Portfolio | 1,873,600 | 1.08% | $72.94M | 0.17% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,834,818 | 1.06% | $71.43M | 3.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,822,133 | 1.05% | $70.94M | 0.21% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,750,000 | 1.01% | $61.18M | 1.06% | May 31, 2026 |
| Lord Abbett Growth Leaders Fund | 1,730,027 | 1.00% | $67.35M | 0.91% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,604,794 | 0.92% | $56.10M | 1.07% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,539,224 | 0.89% | $59.57M | 0.39% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 1,406,858 | 0.81% | $49.18M | 0.83% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew R. Robbins | President and CEO, Director | 657,503 | 0.38% | May 21, 2026 |
| Evan Kearns | Chief Legal Officer | 109,398 | 0.06% | Dec 30, 2025 |
| John Edward Robinson | Chief Scientific Officer | 140,002 | 0.08% | Dec 30, 2025 |
| Jessica Sachs | Chief Medical Officer | 133,938 | 0.08% | Dec 30, 2025 |
| John L. Green | Chief Financial Officer | 131,834 | 0.08% | Dec 30, 2025 |
| Cole Pinnow | Chief Commercial Officer | 97,450 | 0.06% | Dec 19, 2025 |
| Karen Jean Ferrante | Director | – | – | Oct 5, 2026 |
| Arlene Morris | Director | 45,510 | 0.03% | Aug 31, 2026 |
| Christopher W. Cain | Director | – | – | Jun 11, 2026 |
| Matthew Ros | Director | – | – | Jun 11, 2026 |
| Todd Shegog | Director | – | – | Jun 11, 2026 |
| Peter Evan Harwin | Director | – | – | Jun 11, 2026 |
| Funds Management LLC Fairmount | Director | 5,503,418 | 3.17% | Mar 31, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Arlene Morris Director | Aug 27, 2026 | Option exercise | +3,583 | $2.52 | $9.03K | 45,510 |
| Arlene Morris Director | Aug 27, 2026 | Sale(10b5-1 plan) | −42,349 | $37.09 | $1.57M | 3,161 |
| Arlene Morris Director | Aug 27, 2026 | Sale(10b5-1 plan) | −3,161 | $37.54 | $118.66K | 0 |
| Arlene Morris Director | Aug 27, 2026 | Option exercise | +41,927 | $5.64 | $236.47K | 41,927 |
| Andrew R. Robbins President and CEO, Director | May 19, 2026 | Gift | −160,000 | – | – | 497,503 |
| Andrew R. Robbins President and CEO, Director | May 19, 2026 | Gift | +160,000 | – | – | 160,000 |
| Funds Management LLC Fairmount Director | Mar 31, 2026 | Sale | −7,000,000 | $34.66 | $242.62M | 5,503,418 |
| Funds Management LLC Fairmount Director | Mar 31, 2026 | Conversion | +7,000,000 | – | – | 12,503,418 |
| Funds Management LLC Fairmount Director | Jan 22, 2026 | Sale | −3,500,000 | $36.40 | $127.40M | 5,503,418 |
| John L. Green Chief Financial Officer | Dec 26, 2025 | Sale | −77,000 | $38.68 | $2.98M | 131,834 |
| Jessica Sachs Chief Medical Officer | Dec 26, 2025 | Sale | −82,642 | $38.70 | $3.20M | 133,938 |
| John Edward Robinson Chief Scientific Officer | Dec 26, 2025 | Sale | −90,000 | $38.74 | $3.49M | 140,002 |
| Evan Kearns Chief Legal Officer | Dec 26, 2025 | Sale | −65,000 | $38.70 | $2.52M | 109,398 |
| Andrew R. Robbins President and CEO, Director | Dec 17, 2025 | Award | +840,000 | – | – | 1,025,000 |
| Andrew R. Robbins President and CEO, Director | Dec 17, 2025 | Award | +185,000 | – | – | 185,000 |
| Andrew R. Robbins President and CEO, Director | Dec 17, 2025 | Tax withholding | −367,497 | $39.45 | $14.50M | 657,503 |
| John L. Green Chief Financial Officer | Dec 17, 2025 | Award | +300,000 | – | – | 353,841 |
| John L. Green Chief Financial Officer | Dec 17, 2025 | Award | +50,000 | – | – | 53,841 |
| John L. Green Chief Financial Officer | Dec 17, 2025 | Tax withholding | −145,007 | $39.45 | $5.72M | 208,834 |
| Cole Pinnow Chief Commercial Officer | Dec 17, 2025 | Award | +50,000 | – | – | 97,450 |
| Cole Pinnow Chief Commercial Officer | Dec 17, 2025 | Tax withholding | −94,800 | $39.45 | $3.74M | 216,650 |
| Cole Pinnow Chief Commercial Officer | Dec 17, 2025 | Award | +214,000 | – | – | 311,450 |
| Evan Kearns Chief Legal Officer | Dec 17, 2025 | Tax withholding | −125,602 | $39.45 | $4.95M | 174,398 |
| Evan Kearns Chief Legal Officer | Dec 17, 2025 | Award | +260,000 | – | – | 300,000 |
| Evan Kearns Chief Legal Officer | Dec 17, 2025 | Award | +40,000 | – | – | 40,000 |
| Jessica Sachs Chief Medical Officer | Dec 17, 2025 | Award | +50,000 | – | – | 51,296 |
| Jessica Sachs Chief Medical Officer | Dec 17, 2025 | Award | +320,000 | – | – | 371,296 |
| Jessica Sachs Chief Medical Officer | Dec 17, 2025 | Tax withholding | −154,716 | $39.45 | $6.10M | 216,580 |
| John Edward Robinson Chief Scientific Officer | Dec 17, 2025 | Award | +320,000 | – | – | 370,000 |
| John Edward Robinson Chief Scientific Officer | Dec 17, 2025 | Tax withholding | −139,998 | $39.45 | $5.52M | 230,002 |
| John Edward Robinson Chief Scientific Officer | Dec 17, 2025 | Award | +50,000 | – | – | 50,000 |
| Funds Management LLC Fairmount Director | Jul 10, 2025 | Buy | +2,777,777 | $9.00 | $25.00M | 9,003,418 |
| Cole Pinnow Chief Commercial Officer | Jan 14, 2025 | Buy | +43,750 | $7.60 | $332.50K | 45,848 |
| Funds Management LLC Fairmount Director | Jun 10, 2024 | Option exercise | +1,500,000 | – | – | 6,225,641 |
| Funds Management LLC Fairmount Director | Mar 28, 2024 | Other | −286,851 | – | – | 0 |
| Funds Management LLC Fairmount Director | Mar 28, 2024 | Other | +286,851 | – | – | 4,725,641 |
| Funds Management LLC Fairmount 10% owner | Feb 16, 2024 | Award | +1,166,666 | $7.50 | $8.75M | 4,438,790 |
| Funds Management LLC Fairmount 10% owner | Jun 9, 2023 | Buy | +800,000 | $12.00 | $9.60M | 3,272,124 |
| Jessica Sachs Chief Medical Officer | Jun 30, 2022 | Award | +622 | $7.40 | $4.60K | 622 |
| Funds Management LLC Fairmount 10% owner | Jun 16, 2022 | Buy | +1,200,000 | $8.25 | $9.90M | 2,472,124 |
| Jessica Sachs Chief Medical Officer | Dec 31, 2021 | Award | +674 | $6.82 | $4.60K | 674 |
| John L. Green Chief Financial Officer | Apr 26, 2021 | Sale | −17,813 | $8.86 | $157.82K | 3,841 |
| John L. Green Chief Financial Officer | Feb 25, 2021 | Award | +524 | – | – | 21,654 |
| John L. Green Chief Financial Officer | Dec 1, 2020 | Award | +1,748 | – | – | 1,748 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Aug 18, 2020 | Buy | +101,000 | $2.62 | $264.62K | 4,355,273 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Aug 17, 2020 | Buy | +250,000 | $2.57 | $642.50K | 4,254,273 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Aug 14, 2020 | Buy | +100,000 | $2.30 | $230.00K | 4,004,273 |
| Funds Management LLC Fairmount 10% owner | Jul 6, 2020 | Other | +1,147,406 | – | – | 1,147,406 |
| Funds Management LLC Fairmount 10% owner | Jul 6, 2020 | Other | +5,088,497 | – | – | 5,088,497 |
| John L. Green Chief Financial Officer | Jul 6, 2020 | Tax withholding | −31,873 | $2.20 | $70.12K | 77,586 |
| John L. Green Chief Financial Officer | Jul 6, 2020 | Option exercise | +109,459 | – | – | 109,459 |
| Dario Campana 10% owner | May 12, 2020 | Sale | −98,200 | $0.46 | $45.17K | 3,095,114 |
| Dario Campana 10% owner | May 11, 2020 | Sale | −22,281 | $0.46 | $10.25K | 3,271,033 |
| Dario Campana 10% owner | May 11, 2020 | Sale | −77,719 | $0.45 | $34.97K | 3,193,314 |
| Dario Campana 10% owner | May 8, 2020 | Sale | −100,000 | $0.46 | $46.00K | 3,293,314 |
| Dario Campana 10% owner | May 7, 2020 | Sale | −100,000 | $0.41 | $41.00K | 3,393,314 |
| Dario Campana 10% owner | May 6, 2020 | Sale | −1,800 | $0.40 | $720 | 3,493,314 |
| Dario Campana 10% owner | May 5, 2020 | Sale | −135,484 | $0.40 | $54.19K | 3,495,114 |
| Dario Campana 10% owner | May 4, 2020 | Sale | −4,795 | $0.40 | $1.92K | 3,630,598 |
| Dario Campana 10% owner | May 1, 2020 | Sale | −800 | $0.41 | $328 | 3,635,393 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cogent Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,756 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Arlene Morris Director | Aug 27, 2026 | 45,510 | $1.67M | Aug 27, 2026 | Exercise of Stock Options |
| Fairmount Healthcare Fund II L.P. Director | Mar 31, 2026 | 7,000,000 | $242.62M | Mar 31, 2026 | Conversion of Series A Convertible Preferred Stock |
| Fairmount Healthcare Fund II L.P. Director | Jan 22, 2026 | 3,500,000 | $127.40M | Jan 22, 2026 | Purchased in public offering |
| Evan Kearns Officer | Dec 29, 2025 | 65,000 | $2.52M | Dec 26, 2025 | Performance Shares |
| John L. Green Officer | Dec 29, 2025 | 77,000 | $2.98M | Dec 26, 2025 | Performance Shares |
| John Edward Robinson Officer | Dec 29, 2025 | 90,000 | $3.49M | Dec 26, 2025 | Performance Shares |
| Jessica Sachs Officer | Dec 29, 2025 | 82,642 | $3.20M | Dec 26, 2025 | Performance Shares |
Congress trades
1 trade in Cogent Biosciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Bought | Dec 12, 2022 | $1K–15K | Jan 20, 2023 |
See a number that looks wrong?